ID   MUSK_HUMAN              Reviewed;         869 AA.
AC   O15146; Q32MJ8; Q32MJ9; Q5VZW7; Q5VZW8;
DT   19-JUL-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1998, sequence version 1.
DT   10-MAY-2017, entry version 156.
DE   RecName: Full=Muscle, skeletal receptor tyrosine-protein kinase;
DE            EC=2.7.10.1 {ECO:0000269|PubMed:25029443};
DE   AltName: Full=Muscle-specific tyrosine-protein kinase receptor;
DE            Short=MuSK;
DE            Short=Muscle-specific kinase receptor;
DE   Flags: Precursor;
GN   Name=MUSK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND ALTERNATIVE SPLICING
RP   (ISOFORMS 2 AND 3).
RX   PubMed=7546737; DOI=10.1016/0896-6273(95)90146-9;
RA   Valenzuela D.M., Stitt T.N., DiStefano P.S., Rojas E., Mattsson K.,
RA   Compton D.L., Nunez L., Park J.S., Stark J.L., Gies D.R., Thomas S.,
RA   LeBeau M.M., Fernald A.A., Copeland N.G., Jenkins N.A., Burden S.J.,
RA   Glass D.J., Yancopoulos G.D.;
RT   "Receptor tyrosine kinase specific for the skeletal muscle lineage:
RT   expression in embryonic muscle, at the neuromuscular junction, and
RT   after injury.";
RL   Neuron 15:573-584(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   INTERACTION WITH DOK7.
RX   PubMed=20603078; DOI=10.1016/j.molcel.2010.06.007;
RA   Bergamin E., Hallock P.T., Burden S.J., Hubbard S.R.;
RT   "The cytoplasmic adaptor protein Dok7 activates the receptor tyrosine
RT   kinase MuSK via dimerization.";
RL   Mol. Cell 39:100-109(2010).
RN   [5]
RP   NEDDYLATION.
RX   PubMed=20596523; DOI=10.1371/journal.pone.0011332;
RA   Del Rincon S.V., Rogers J., Widschwendter M., Sun D., Sieburg H.B.,
RA   Spruck C.;
RT   "Development and validation of a method for profiling post-
RT   translational modification activities using protein microarrays.";
RL   PLoS ONE 5:E11332-E11332(2010).
RN   [6]
RP   CATALYTIC ACTIVITY, COFACTOR, PHOSPHORYLATION, AND MUTAGENESIS OF
RP   GLY-584; LYS-609 AND ASP-743.
RX   PubMed=25029443; DOI=10.1371/journal.pone.0102695;
RA   Bainbridge T.W., DeAlmeida V.I., Izrael-Tomasevic A., Chalouni C.,
RA   Pan B., Goldsmith J., Schoen A.P., Quinones G.A., Kelly R., Lill J.R.,
RA   Sandoval W., Costa M., Polakis P., Arnott D., Rubinfeld B.,
RA   Ernst J.A.;
RT   "Evolutionary divergence in the catalytic activity of the CAM-1, ROR1
RT   and ROR2 kinase domains.";
RL   PLoS ONE 9:E102695-E102695(2014).
RN   [7]
RP   VARIANT CMS9 MET-790, AND INVOLVEMENT IN CMS9.
RX   PubMed=15496425; DOI=10.1093/hmg/ddh333;
RA   Chevessier F., Faraut B., Ravel-Chapuis A., Richard P., Gaudon K.,
RA   Bauche S., Prioleau C., Herbst R., Goillot E., Ioos C., Azulay J.-P.,
RA   Attarian S., Leroy J.-P., Fournier E., Legay C., Schaeffer L.,
RA   Koenig J., Fardeau M., Eymard B., Pouget J., Hantai D.;
RT   "MUSK, a new target for mutations causing congenital myasthenic
RT   syndrome.";
RL   Hum. Mol. Genet. 13:3229-3240(2004).
RN   [8]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLY-27; MET-100; GLU-107; GLY-159;
RP   SER-222; ILE-413; PHE-629; ALA-644; SER-664; LEU-696; ASP-782;
RP   SER-819; LEU-829 AND HIS-858.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [9]
RP   VARIANT CMS9 ARG-344.
RX   PubMed=19949040; DOI=10.1212/WNL.0b013e3181c3fce9;
RA   Mihaylova V., Salih M.A., Mukhtar M.M., Abuzeid H.A., El-Sadig S.M.,
RA   von der Hagen M., Huebner A., Nurnberg G., Abicht A., Muller J.S.,
RA   Lochmuller H., Guergueltcheva V.;
RT   "Refinement of the clinical phenotype in musk-related congenital
RT   myasthenic syndromes.";
RL   Neurology 73:1926-1928(2009).
RN   [10]
RP   VARIANTS CMS9 ILE-605 AND VAL-727, AND CHARACTERIZATION OF VARIANTS
RP   CMS9 ILE-605 AND VAL-727.
RX   PubMed=20371544; DOI=10.1093/hmg/ddq110;
RA   Maselli R.A., Arredondo J., Cagney O., Ng J.J., Anderson J.A.,
RA   Williams C., Gerke B.J., Soliven B., Wollmann R.L.;
RT   "Mutations in MUSK causing congenital myasthenic syndrome impair MuSK-
RT   Dok-7 interaction.";
RL   Hum. Mol. Genet. 19:2370-2379(2010).
RN   [11]
RP   VARIANT CMS9 VAL-835, AND SUBCELLULAR LOCATION.
RX   PubMed=23326516; DOI=10.1371/journal.pone.0053826;
RA   Ben Ammar A., Soltanzadeh P., Bauche S., Richard P., Goillot E.,
RA   Herbst R., Gaudon K., Huze C., Schaeffer L., Yamanashi Y., Higuchi O.,
RA   Taly A., Koenig J., Leroy J.P., Hentati F., Najmabadi H., Kahrizi K.,
RA   Ilkhani M., Fardeau M., Eymard B., Hantai D.;
RT   "A mutation causes MuSK reduced sensitivity to agrin and congenital
RT   myasthenia.";
RL   PLoS ONE 8:E53826-E53826(2013).
RN   [12]
RP   VARIANT FADS THR-575, INVOLVEMENT IN FADS, CHARACTERIZATION OF VARIANT
RP   FADS THR-575, AND FUNCTION.
RX   PubMed=25537362; DOI=10.1038/ejhg.2014.273;
RA   Tan-Sindhunata M.B., Mathijssen I.B., Smit M., Baas F., de Vries J.I.,
RA   van der Voorn J.P., Kluijt I., Hagen M.A., Blom E.W., Sistermans E.,
RA   Meijers-Heijboer H., Waisfisz Q., Weiss M.M., Groffen A.J.;
RT   "Identification of a Dutch founder mutation in MUSK causing fetal
RT   akinesia deformation sequence.";
RL   Eur. J. Hum. Genet. 23:1151-1157(2015).
RN   [13]
RP   VARIANT CMS9 GLU-38.
RX   PubMed=24183479; DOI=10.1016/j.nmd.2013.08.002;
RA   Gallenmuller C., Muller-Felber W., Dusl M., Stucka R.,
RA   Guergueltcheva V., Blaschek A., von der Hagen M., Huebner A.,
RA   Muller J.S., Lochmuller H., Abicht A.;
RT   "Salbutamol-responsive limb-girdle congenital myasthenic syndrome due
RT   to a novel missense mutation and heteroallelic deletion in MUSK.";
RL   Neuromuscul. Disord. 24:31-35(2014).
RN   [14]
RP   INVOLVEMENT IN FADS.
RX   PubMed=25612909; DOI=10.1136/jmedgenet-2014-102730;
RA   Wilbe M., Ekvall S., Eurenius K., Ericson K., Casar-Borota O.,
RA   Klar J., Dahl N., Ameur A., Anneren G., Bondeson M.L.;
RT   "MuSK: a new target for lethal fetal akinesia deformation sequence
RT   (FADS).";
RL   J. Med. Genet. 52:195-202(2015).
CC   -!- FUNCTION: Receptor tyrosine kinase which plays a central role in
CC       the formation and the maintenance of the neuromuscular junction
CC       (NMJ), the synapse between the motor neuron and the skeletal
CC       muscle (PubMed:25537362). Recruitment of AGRIN by LRP4 to the MUSK
CC       signaling complex induces phosphorylation and activation of MUSK,
CC       the kinase of the complex. The activation of MUSK in myotubes
CC       regulates the formation of NMJs through the regulation of
CC       different processes including the specific expression of genes in
CC       subsynaptic nuclei, the reorganization of the actin cytoskeleton
CC       and the clustering of the acetylcholine receptors (AChR) in the
CC       postsynaptic membrane. May regulate AChR phosphorylation and
CC       clustering through activation of ABL1 and Src family kinases which
CC       in turn regulate MUSK. DVL1 and PAK1 that form a ternary complex
CC       with MUSK are also important for MUSK-dependent regulation of AChR
CC       clustering. May positively regulate Rho family GTPases through
CC       FNTA. Mediates the phosphorylation of FNTA which promotes
CC       prenylation, recruitment to membranes and activation of RAC1 a
CC       regulator of the actin cytoskeleton and of gene expression. Other
CC       effectors of the MUSK signaling include DNAJA3 which functions
CC       downstream of MUSK. May also play a role within the central
CC       nervous system by mediating cholinergic responses, synaptic
CC       plasticity and memory formation (By similarity). {ECO:0000250,
CC       ECO:0000269|PubMed:25537362}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:25029443}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:25029443};
CC   -!- ENZYME REGULATION: Positively regulated by CK2. {ECO:0000250}.
CC   -!- SUBUNIT: Monomer (By similarity). Homodimer (Probable). Interacts
CC       with LRP4; the heterodimer forms an AGRIN receptor complex that
CC       binds AGRIN resulting in activation of MUSK (By similarity). Forms
CC       a heterotetramer composed of 2 DOK7 and 2 MUSK molecules which
CC       facilitates MUSK trans-autophosphorylation on tyrosine residue and
CC       activation. Interacts (via cytoplasmic part) with DOK7 (via IRS-
CC       type PTB domain); requires MUSK phosphorylation. Interacts with
CC       DVL1 (via DEP domain); the interaction is direct and mediates the
CC       formation of a DVL1, MUSK and PAK1 ternary complex involved in
CC       AChR clustering (By similarity). Interacts with PDZRN3; this
CC       interaction is enhanced by agrin (By similarity). Interacts with
CC       FNTA; the interaction is direct and mediates AGRIN-induced
CC       phosphorylation and activation of FNTA (By similarity). Interacts
CC       with CSNK2B; mediates regulation by CK2 (By similarity). Interacts
CC       (via the cytoplasmic domain) with DNAJA3 (By similarity).
CC       Interacts with NSF; may regulate MUSK endocytosis and activity (By
CC       similarity). Interacts with CAV3; may regulate MUSK signaling (By
CC       similarity). Interacts with RNF31 (By similarity).
CC       {ECO:0000250|UniProtKB:Q62838, ECO:0000305}.
CC   -!- INTERACTION:
CC       P08238:HSP90AB1; NbExp=2; IntAct=EBI-6423196, EBI-352572;
CC   -!- SUBCELLULAR LOCATION: Cell junction, synapse, postsynaptic cell
CC       membrane {ECO:0000269|PubMed:23326516}; Single-pass type I
CC       membrane protein {ECO:0000305}. Note=Colocalizes with
CC       acetylcholine receptors (AChR) to the postsynaptic cell membrane
CC       of the neuromuscular junction. {ECO:0000269|PubMed:23326516}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=O15146-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O15146-2; Sequence=VSP_035958, VSP_035959, VSP_035960;
CC       Name=3;
CC         IsoId=O15146-3; Sequence=VSP_035959, VSP_035960;
CC   -!- PTM: Ubiquitinated by PDZRN3. Ubiquitination promotes endocytosis
CC       and lysosomal degradation (By similarity). {ECO:0000250}.
CC   -!- PTM: Phosphorylated. Phosphorylation is induced by AGRIN in a
CC       LRP4-dependent manner (By similarity). Autophosphorylated
CC       (PubMed:25029443). Autophosphorylation at Tyr-554 is required for
CC       interaction with DOK7 which in turn stimulates the phosphorylation
CC       and the activation of MUSK (By similarity).
CC       {ECO:0000250|UniProtKB:Q62838, ECO:0000269|PubMed:25029443}.
CC   -!- PTM: Neddylated. {ECO:0000269|PubMed:20596523}.
CC   -!- DISEASE: Myasthenic syndrome, congenital, 9, associated with
CC       acetylcholine receptor deficiency (CMS9) [MIM:616325]: A form of
CC       congenital myasthenic syndrome, a group of disorders characterized
CC       by failure of neuromuscular transmission, including pre-synaptic,
CC       synaptic, and post-synaptic disorders that are not of autoimmune
CC       origin. Clinical features are easy fatigability and muscle
CC       weakness affecting the axial and limb muscles (with hypotonia in
CC       early-onset forms), the ocular muscles (leading to ptosis and
CC       ophthalmoplegia), and the facial and bulbar musculature (affecting
CC       sucking and swallowing, and leading to dysphonia). The symptoms
CC       fluctuate and worsen with physical effort. CMS9 is a disorder of
CC       postsynaptic neuromuscular transmission, due to deficiency of AChR
CC       at the endplate that results in low amplitude of the miniature
CC       endplate potential and current. {ECO:0000269|PubMed:15496425,
CC       ECO:0000269|PubMed:19949040, ECO:0000269|PubMed:20371544,
CC       ECO:0000269|PubMed:23326516, ECO:0000269|PubMed:24183479}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry. MUSK mutations lead to decreased agrin-
CC       dependent AChR aggregation, a critical step in the formation of
CC       the neuromuscular junction.
CC   -!- DISEASE: Fetal akinesia deformation sequence (FADS) [MIM:208150]:
CC       A clinically and genetically heterogeneous group of disorders with
CC       congenital malformations related to impaired fetal movement.
CC       Clinical features include fetal akinesia, intrauterine growth
CC       retardation, polyhydramnios, arthrogryposis, pulmonary hypoplasia,
CC       craniofacial abnormalities, and cryptorchidism.
CC       {ECO:0000269|PubMed:25537362, ECO:0000269|PubMed:25612909}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAH69977.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=CAH69978.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=CAI17349.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=CAI17350.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=MuSK entry;
CC       URL="https://en.wikipedia.org/wiki/MuSK_protein";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF006464; AAB63044.1; -; mRNA.
DR   EMBL; AL157881; CAH69977.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AL513328; CAH69977.1; JOINED; Genomic_DNA.
DR   EMBL; AL513328; CAI17349.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AL157881; CAI17349.1; JOINED; Genomic_DNA.
DR   EMBL; AL157881; CAH69978.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AL513328; CAH69978.1; JOINED; Genomic_DNA.
DR   EMBL; AL513328; CAI17350.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AL157881; CAI17350.1; JOINED; Genomic_DNA.
DR   EMBL; BC109098; AAI09099.1; -; mRNA.
DR   EMBL; BC109099; AAI09100.1; -; mRNA.
DR   CCDS; CCDS48005.1; -. [O15146-1]
DR   CCDS; CCDS75874.1; -. [O15146-2]
DR   RefSeq; NP_001159752.1; NM_001166280.1. [O15146-2]
DR   RefSeq; NP_001159753.1; NM_001166281.1. [O15146-3]
DR   RefSeq; NP_005583.1; NM_005592.3. [O15146-1]
DR   UniGene; Hs.521653; -.
DR   ProteinModelPortal; O15146; -.
DR   SMR; O15146; -.
DR   BioGrid; 110679; 6.
DR   IntAct; O15146; 6.
DR   MINT; MINT-2983114; -.
DR   STRING; 9606.ENSP00000363571; -.
DR   BindingDB; O15146; -.
DR   ChEMBL; CHEMBL5684; -.
DR   GuidetoPHARMACOLOGY; 1847; -.
DR   iPTMnet; O15146; -.
DR   PhosphoSitePlus; O15146; -.
DR   BioMuta; MUSK; -.
DR   PaxDb; O15146; -.
DR   PeptideAtlas; O15146; -.
DR   PRIDE; O15146; -.
DR   DNASU; 4593; -.
DR   Ensembl; ENST00000189978; ENSP00000189978; ENSG00000030304. [O15146-2]
DR   Ensembl; ENST00000374448; ENSP00000363571; ENSG00000030304. [O15146-1]
DR   GeneID; 4593; -.
DR   KEGG; hsa:4593; -.
DR   UCSC; uc064vai.1; human. [O15146-1]
DR   CTD; 4593; -.
DR   DisGeNET; 4593; -.
DR   GeneCards; MUSK; -.
DR   GeneReviews; MUSK; -.
DR   HGNC; HGNC:7525; MUSK.
DR   MalaCards; MUSK; -.
DR   MIM; 208150; phenotype.
DR   MIM; 601296; gene.
DR   MIM; 616325; phenotype.
DR   neXtProt; NX_O15146; -.
DR   OpenTargets; ENSG00000030304; -.
DR   Orphanet; 98913; Postsynaptic congenital myasthenic syndromes.
DR   PharmGKB; PA31326; -.
DR   eggNOG; ENOG410IMMJ; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118818; -.
DR   HOGENOM; HOG000044461; -.
DR   HOVERGEN; HBG052539; -.
DR   InParanoid; O15146; -.
DR   KO; K05129; -.
DR   OMA; KGYCAQY; -.
DR   OrthoDB; EOG091G016V; -.
DR   PhylomeDB; O15146; -.
DR   TreeFam; TF106465; -.
DR   Reactome; R-HSA-3000178; ECM proteoglycans.
DR   SignaLink; O15146; -.
DR   SIGNOR; O15146; -.
DR   ChiTaRS; MUSK; human.
DR   GenomeRNAi; 4593; -.
DR   PRO; PR:O15146; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; ENSG00000030304; -.
DR   CleanEx; HS_MUSK; -.
DR   ExpressionAtlas; O15146; baseline and differential.
DR   Genevisible; O15146; HS.
DR   GO; GO:0030054; C:cell junction; IEA:UniProtKB-KW.
DR   GO; GO:0005887; C:integral component of plasma membrane; ISS:UniProtKB.
DR   GO; GO:0031594; C:neuromuscular junction; ISS:UniProtKB.
DR   GO; GO:0045211; C:postsynaptic membrane; ISS:UniProtKB.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; ISS:UniProtKB.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0030154; P:cell differentiation; IEA:UniProtKB-KW.
DR   GO; GO:0007613; P:memory; ISS:UniProtKB.
DR   GO; GO:0007275; P:multicellular organism development; IEA:UniProtKB-KW.
DR   GO; GO:0007528; P:neuromuscular junction development; IDA:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; ISS:UniProtKB.
DR   GO; GO:2000541; P:positive regulation of protein geranylgeranylation; ISS:UniProtKB.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IMP:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; ISS:UniProtKB.
DR   GO; GO:0008582; P:regulation of synaptic growth at neuromuscular junction; ISS:UniProtKB.
DR   GO; GO:0071340; P:skeletal muscle acetylcholine-gated channel clustering; ISS:UniProtKB.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; TAS:ProtInc.
DR   Gene3D; 1.10.2000.10; -; 1.
DR   Gene3D; 2.60.40.10; -; 3.
DR   InterPro; IPR020067; Frizzled_dom.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   Pfam; PF01392; Fz; 1.
DR   Pfam; PF07679; I-set; 2.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00409; IG; 3.
DR   SMART; SM00408; IGc2; 3.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 3.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50038; FZ; 1.
DR   PROSITE; PS50835; IG_LIKE; 3.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Cell junction; Cell membrane;
KW   Complete proteome; Congenital myasthenic syndrome;
KW   Developmental protein; Differentiation; Disease mutation;
KW   Disulfide bond; Glycoprotein; Immunoglobulin domain; Kinase;
KW   Magnesium; Membrane; Metal-binding; Muscle protein;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism;
KW   Postsynaptic cell membrane; Receptor; Reference proteome; Repeat;
KW   Signal; Synapse; Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL        1     23       {ECO:0000255}.
FT   CHAIN        24    869       Muscle, skeletal receptor tyrosine-
FT                                protein kinase.
FT                                /FTId=PRO_0000024446.
FT   TOPO_DOM     24    495       Extracellular. {ECO:0000255}.
FT   TRANSMEM    496    516       Helical. {ECO:0000255}.
FT   TOPO_DOM    517    869       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       28    116       Ig-like 1.
FT   DOMAIN      121    205       Ig-like 2.
FT   DOMAIN      212    302       Ig-like 3.
FT   DOMAIN      312    450       FZ. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00090}.
FT   DOMAIN      575    856       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     581    589       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE    725    725       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     609    609       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     554    554       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     681    681       Phosphoserine; by CK2. {ECO:0000250}.
FT   MOD_RES     698    698       Phosphoserine; by CK2. {ECO:0000250}.
FT   MOD_RES     755    755       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   CARBOHYD    222    222       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    338    338       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000250}.
FT   DISULFID     49     99       {ECO:0000250}.
FT   DISULFID     98    112       {ECO:0000250}.
FT   DISULFID    142    190       {ECO:0000250}.
FT   DISULFID    233    282       {ECO:0000250}.
FT   DISULFID    317    382       {ECO:0000250}.
FT   DISULFID    325    375       {ECO:0000250}.
FT   DISULFID    366    406       {ECO:0000250}.
FT   DISULFID    394    447       {ECO:0000250}.
FT   DISULFID    398    434       {ECO:0000250}.
FT   VAR_SEQ     209    209       E -> EEESEPEQDTK (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_035958.
FT   VAR_SEQ     307    394       Missing (in isoform 2 and isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_035959.
FT   VAR_SEQ     454    462       DYNKENLKT -> A (in isoform 2 and isoform
FT                                3). {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_035960.
FT   VARIANT      27     27       A -> G (in dbSNP:rs56054734).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041748.
FT   VARIANT      38     38       D -> E (in CMS9; dbSNP:rs775587809).
FT                                {ECO:0000269|PubMed:24183479}.
FT                                /FTId=VAR_072785.
FT   VARIANT     100    100       T -> M (in dbSNP:rs35142681).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041749.
FT   VARIANT     107    107       G -> E (in dbSNP:rs55786136).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041750.
FT   VARIANT     159    159       S -> G (in dbSNP:rs35176182).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041751.
FT   VARIANT     222    222       N -> S (in dbSNP:rs55826142).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041752.
FT   VARIANT     344    344       P -> R (in CMS9; dbSNP:rs387906803).
FT                                {ECO:0000269|PubMed:19949040}.
FT                                /FTId=VAR_072786.
FT   VARIANT     413    413       M -> I (in dbSNP:rs2274419).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_021930.
FT   VARIANT     575    575       I -> T (in FADS; reduces agrin-dependent
FT                                AChR aggregation and tyrosin kinase
FT                                activity in developing neuromuscular
FT                                junction; dbSNP:rs751889864).
FT                                {ECO:0000269|PubMed:25537362}.
FT                                /FTId=VAR_072787.
FT   VARIANT     605    605       M -> I (in CMS9; affects interaction with
FT                                DOK7 and impairs MUSK phosphorylation;
FT                                altered AChR clustering;
FT                                dbSNP:rs766640370).
FT                                {ECO:0000269|PubMed:20371544}.
FT                                /FTId=VAR_066604.
FT   VARIANT     629    629       L -> F (in dbSNP:rs34267283).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041753.
FT   VARIANT     644    644       V -> A (in dbSNP:rs41279055).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041754.
FT   VARIANT     664    664       N -> S (in dbSNP:rs55963442).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041755.
FT   VARIANT     696    696       P -> L (in dbSNP:rs56126328).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041756.
FT   VARIANT     727    727       A -> V (in CMS9; affects interaction with
FT                                DOK7 and impairs MUSK phosphorylation;
FT                                altered AChR clustering;
FT                                dbSNP:rs397515450).
FT                                {ECO:0000269|PubMed:20371544}.
FT                                /FTId=VAR_066605.
FT   VARIANT     782    782       E -> D (in dbSNP:rs34614566).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041757.
FT   VARIANT     790    790       V -> M (in CMS9; does not affect
FT                                catalytic kinase activity; reduces
FT                                protein expression and stability;
FT                                dbSNP:rs199476083).
FT                                {ECO:0000269|PubMed:15496425}.
FT                                /FTId=VAR_023046.
FT   VARIANT     819    819       N -> S (in a lung neuroendocrine
FT                                carcinoma sample; somatic mutation;
FT                                dbSNP:rs757577755).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041758.
FT   VARIANT     829    829       V -> L (in dbSNP:rs578430).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_033837.
FT   VARIANT     835    835       M -> V (in CMS9; reduces AChR aggregation
FT                                in developing neuromuscular junction).
FT                                {ECO:0000269|PubMed:23326516}.
FT                                /FTId=VAR_072788.
FT   VARIANT     858    858       R -> H (in dbSNP:rs34115159).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041759.
FT   MUTAGEN     584    584       G->C,D: Mild decrease in kinase activity.
FT                                {ECO:0000269|PubMed:25029443}.
FT   MUTAGEN     609    609       K->R: Severe loss of kinase activity.
FT                                {ECO:0000269|PubMed:25029443}.
FT   MUTAGEN     743    743       D->N: Severe loss of kinase activity.
FT                                {ECO:0000269|PubMed:25029443}.
SQ   SEQUENCE   869 AA;  97056 MW;  3DDC20E179FA010C CRC64;
     MRELVNIPLV HILTLVAFSG TEKLPKAPVI TTPLETVDAL VEEVATFMCA VESYPQPEIS
     WTRNKILIKL FDTRYSIREN GQLLTILSVE DSDDGIYCCT ANNGVGGAVE SCGALQVKMK
     PKITRPPINV KIIEGLKAVL PCTTMGNPKP SVSWIKGDSP LRENSRIAVL ESGSLRIHNV
     QKEDAGQYRC VAKNSLGTAY SKVVKLEVEV FARILRAPES HNVTFGSFVT LHCTATGIPV
     PTITWIENGN AVSSGSIQES VKDRVIDSRL QLFITKPGLY TCIATNKHGE KFSTAKAAAT
     ISIAEWSKPQ KDNKGYCAQY RGEVCNAVLA KDALVFLNTS YADPEEAQEL LVHTAWNELK
     VVSPVCRPAA EALLCNHIFQ ECSPGVVPTP IPICREYCLA VKELFCAKEW LVMEEKTHRG
     LYRSEMHLLS VPECSKLPSM HWDPTACARL PHLDYNKENL KTFPPMTSSK PSVDIPNLPS
     SSSSSFSVSP TYSMTVIISI MSSFAIFVLL TITTLYCCRR RKQWKNKKRE SAAVTLTTLP
     SELLLDRLHP NPMYQRMPLL LNPKLLSLEY PRNNIEYVRD IGEGAFGRVF QARAPGLLPY
     EPFTMVAVKM LKEEASADMQ ADFQREAALM AEFDNPNIVK LLGVCAVGKP MCLLFEYMAY
     GDLNEFLRSM SPHTVCSLSH SDLSMRAQVS SPGPPPLSCA EQLCIARQVA AGMAYLSERK
     FVHRDLATRN CLVGENMVVK IADFGLSRNI YSADYYKANE NDAIPIRWMP PESIFYNRYT
     TESDVWAYGV VLWEIFSYGL QPYYGMAHEE VIYYVRDGNI LSCPENCPVE LYNLMRLCWS
     KLPADRPSFT SIHRILERMC ERAEGTVSV
//
